These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9057364)

  • 1. Evaluation of safety and efficacy of azithromycin in lower respiratory tract infections (LRTI).
    Adhikari P; Hegde BM; Pereira P; Bhat P; Chowta N; Ramesh KV; Venkatadri TV; Pai MM
    Indian J Med Sci; 1996 Sep; 50(9):313-7. PubMed ID: 9057364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections.
    Ferwerda A; Moll HA; Hop WC; Kouwenberg JM; Tjon Pian Gi CV; Robben SG; de Groot R
    J Antimicrob Chemother; 2001 Apr; 47(4):441-6. PubMed ID: 11266417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and tolerance of azithromycin in respiratory tract infections in children].
    Toscano MA; Marzullo E; Minneci MS; Salmeri M; Chinnici V; Emanuele A; Gulino A; Malafarina D; Mannino G; Marletta V
    Minerva Pediatr; 1995 Jun; 47(6):249-60. PubMed ID: 7476752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pattern of micro-organisms and the efficacy of new macrolide in acute lower respiratory tract infections.
    Soepandi P; Mangunnegoro H; Yunus F; Gunawan J
    Respirology; 1998 Jun; 3(2):113-7. PubMed ID: 9692520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open, multicentre, comparative study of the efficacy and safety of azithromycin and co-amoxiclav in the treatment of upper and lower respiratory tract infections in children. The Paediatric Azithromycin Study Group.
    Lauvau DV; Verbist L
    J Int Med Res; 1997; 25(5):285-95. PubMed ID: 9364291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study.
    Gris P
    J Antimicrob Chemother; 1996 Jun; 37 Suppl C():93-101. PubMed ID: 8818850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azithromycin: 3-day versus 5-day course in the treatment of respiratory tract infections in children. Croatian Azithromycin Study Group.
    Ficnar B; Huzjak N; Oreskovic K; Matrapazovski M; Klinar I
    J Chemother; 1997 Feb; 9(1):38-43. PubMed ID: 9106016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety and tolerability of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infections.
    Laurent K
    J Antimicrob Chemother; 1996 Jun; 37 Suppl C():115-24. PubMed ID: 8818852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azithromycin for acute lower respiratory tract infections.
    Laopaiboon M; Panpanich R; Swa Mya K
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD001954. PubMed ID: 25749735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azithromycin for acute lower respiratory tract infections.
    Panpanich R; Lerttrakarnnon P; Laopaiboon M
    Cochrane Database Syst Rev; 2008 Jan; (1):CD001954. PubMed ID: 18253999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, comparative study to evaluate the efficacy and tolerability of a 3-day course of azithromycin versus a 10-day course of co-amoxiclav as treatment of adult patients with lower respiratory tract infections.
    Zachariah J
    J Antimicrob Chemother; 1996 Jun; 37 Suppl C():103-13. PubMed ID: 8818851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of azithromycin in the treatment of respiratory infections in children.
    Lakoš AK; Pangerčić A; Gašparić M; Kukuruzović MM; Kovačić D; Baršić B
    Curr Med Res Opin; 2012 Jan; 28(1):155-62. PubMed ID: 22070514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open comparative study of azithromycin and roxithromycin in the treatment of acute upper respiratory tract infections.
    Müller O
    J Antimicrob Chemother; 1996 Jun; 37 Suppl C():83-92. PubMed ID: 8818849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections.
    Roord JJ; Wolf BH; Gossens MM; Kimpen JL
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2765-8. PubMed ID: 9124837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azithromycin and lower respiratory tract infections.
    Blasi F; Cazzola M; Tarsia P; Cosentini R; Aliberti S; Santus P; Allegra L
    Expert Opin Pharmacother; 2005 Oct; 6(13):2335-51. PubMed ID: 16218893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacovigilance study of azithromycin tablets (500 mg) in the treatment of adult patients with respiratory tract infections].
    Alvarez MP; Simón M; Sánchez S; Apaloaza I; Prieto J
    Rev Esp Quimioter; 2000 Sep; 13(3):297-305. PubMed ID: 11086281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comment on: Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data.
    Kirby A
    J Antimicrob Chemother; 2015 Nov; 70(11):3170. PubMed ID: 26157112
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data-authors' response.
    Zhanel GG; Wolter KD; Karlowsky JA
    J Antimicrob Chemother; 2015 Nov; 70(11):3170-1. PubMed ID: 26242414
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data.
    Zhanel GG; Wolter KD; Calciu C; Hogan P; Low DE; Weiss K; Karlowsky JA
    J Antimicrob Chemother; 2014 Oct; 69(10):2835-40. PubMed ID: 24920652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SAFETY AND EFFECTIVENESS OF AZITHROMYCIN IN THE TREATMENT OF LOWER RESPIRATORY INFECTIONS: AN INTERNATIONAL, MULTICENTER, NON-COMPARATIVE STUDY.
    Gašparić M; Penezić A; Kolumbić-Lakoš A; Kovačić D; Kukuruzović MM; Baršić B
    Acta Clin Croat; 2015 Jun; 54(2):149-58. PubMed ID: 26489107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.